Who are C-Tb's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): recombinant subunit Herpes zoster vaccine, RSV prefusion F protein-based vaccine, RSVpreF 120 µg, recombinant adjuvanted zoster vaccine, Zoster Vaccine Recombinant, Zoster Vaccine Recombinant, Adjuvanted.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/c-tb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

C-Tb — Competitive Intelligence Brief

C-Tb (C-Tb) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Subunit vaccine. Area: Infectious Disease / Immunology.

phase 3 Subunit vaccine Mycobacterium tuberculosis antigens (ESAT-6, CFP-10) Infectious Disease / Immunology Biologic Live · refreshed every 30 min

Target snapshot

C-Tb (C-Tb) — Statens Serum Institut. C-Tb is a tuberculosis vaccine candidate that stimulates immune responses against Mycobacterium tuberculosis antigens to prevent or treat tuberculosis infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
C-Tb TARGET	C-Tb	Statens Serum Institut	phase 3	Subunit vaccine	Mycobacterium tuberculosis antigens (ESAT-6, CFP-10)
recombinant subunit Herpes zoster vaccine	recombinant subunit Herpes zoster vaccine	University Health Network, Toronto	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
RSV prefusion F protein-based vaccine	rsv-prefusion-f-protein-based-vaccine	Pfizer Inc.	marketed	Viral protein subunit vaccine	Respiratory syncytial virus fusion (F) protein
RSVpreF 120 µg	rsvpref-120-g	Pfizer	marketed	Recombinant subunit vaccine	Prefusion form of the RSV F protein
recombinant adjuvanted zoster vaccine	recombinant adjuvanted zoster vaccine	Wuerzburg University Hospital	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant	Zoster Vaccine Recombinant	University of Colorado, Denver	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant, Adjuvanted	Zoster Vaccine Recombinant, Adjuvanted	Wuhan BravoVax Co., Ltd.	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Subunit vaccine class)

GlaxoSmithKline · 1 drug in this class
Statens Serum Institut · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). C-Tb — Competitive Intelligence Brief. https://druglandscape.com/ci/c-tb. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab